Tiffanie McDowell
Areas of Focus
Overview
Tiffanie McDowell is a partner in Crowell & Moring's Orange County office, where she practices in the firm's Antitrust and Competition Group and Health Care groups. Her practice focuses primarily on complex antitrust litigation, pharmaceutical advertising, pricing and access issues, and health care recovery.
Career & Education
- University of Missouri, B.S., cum laude, political science, 2006
- University of Missouri, B.A., cum laude, international studies, 2006
- University of Missouri, B.B.A., cum laude, international business, 2006
- University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
- University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
- California
Tiffanie's Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Client Alert | 4 min read | 05.07.24
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
Client Alert | 4 min read | 04.18.24
Insights
Tripped at Customs: EU Seizures of Indian Generic Pharmaceutical Drugs in Transit
|08.19.15
Practitioner Treatise on International Business Vol. 2, Ralph Folsom ed.
Industries
Tiffanie's Insights
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Client Alert | 4 min read | 05.07.24
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
Client Alert | 4 min read | 04.18.24